Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Structure dictates effectiveness, safety in nanomedicine

Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue this precise control should be applied to optimize new nanomedicines.

Published by
ScienceDaily
Evidence type
Laboratory

Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue this precise control should be applied to optimize new nanomedicines.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at ScienceDaily.

Drug Delivery & Nanomedicine

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Structure dictates effectiveness, safety in nanomedicine | Brilliant Blue Biosciences